CStone Pharmaceuticals WKN: A2PEFW ISIN: KYG2588M1006 Forum: Aktien Thema: Hauptdiskussion

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-gavreto-gains-inclusion-in-chinas-national-reimbursement-drug-list

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-sets-march-board-meeting-and-investor-call-to-detail-2025-results-and-oncology-pipeline-progress

https://de.marketscreener.com/boerse-nachrichten/cstone-pharmaceuticals-veroeffentlicht-ergebnisse-fuer-das-am-31-dezember-2025-endende-geschaeftsjahr-ce7e51dbd98ef32d

Welcome back pennystock🙈🙈

https://simplywall-st.cdn.ampproject.org/v/s/simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/this-insider-has-just-sold-shares-in-cstone-pharmaceuticals-1/amp?amp_gsa=1&amp_js_v=a9&usqp=mq331AQIUAKwASCAAgM%3D#amp_tf=Von%20%251%24s&aoh=17580890492538&referrer=https%3A%2F%2Fwww.google.com&ampshare=https%3A%2F%2Fsimplywall.st%2Fstocks%2Fhk%2Fpharmaceuticals-biotech%2Fhkg-2616%2Fcstone-pharmaceuticals-shares%2Fnews%2Fthis-insider-has-just-sold-shares-in-cstone-pharmaceuticals-1

Insiderverkäufe übersteigen die Insiderkäufe. Kein gutes Zeichen

Gewinnmitnahmen nach 130 Prozent Anstieg in 3 Monaten.

Kann mir jemand erklären warum die Aktie so dermaßen abstürzt?

https://www.cstonepharma.com/en/html/news/3833.html

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-schedules-board-meeting-for-interim-results-review

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-advances-phase-iii-study-for-liver-cancer-treatment

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-phase-iii-study-on-cs1001-for-nsclc-a-market-game-changer

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-completes-hk467-28-million-share-placing-to-boost-rd

https://www.ainvest.com/news/cstone-pharma-sell-1-100-million-shares-placement-2507/

https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-unveils-promising-bispecific-antibody-targets-for-autoimmune-diseases